PolyPid Ltd. (PYPD) has released an update.
PolyPid Ltd., a late-stage biopharma company, is advancing its Phase 3 SHIELD II trial with over 200 patients enrolled for D-PLEX100, aiming to prevent surgical site infections in abdominal surgeries. The trial’s interim analysis is projected for mid-2024, with top-line results expected later that year. Financially, the company secured $16 million through private financing, extending its cash runway into Q4 2024, with the possibility of an additional $19 million pending positive interim results.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.